<DOC>
	<DOCNO>NCT00809276</DOCNO>
	<brief_summary>The purpose research find effective least toxic way prevent GVHD BMT .</brief_summary>
	<brief_title>Allo BMT Using Matched Related/Unrelated Donors With FluBu HiCY</brief_title>
	<detailed_description>A person cancer blood lymph gland treat bone marrow transplantation ( BMT ) . BMT develop several decade research animal human subject effective treatment various malignant nonmalignant hematologic disease . Many hematologic malignancy successfully treat combination high-dose chemotherapy chemo-radiotherapy transplantation allogeneic bone marrow peripheral blood stem cell ( alloBMT ) However , possible side effect BMT graft versus host disease ( GVHD ) . GVHD occur cell donor 's immune system , present bone marrow , attack BMT recipient 's normal tissue . Prevention GVHD important success bone marrow transplant . This research do find effective least toxic way prevent GVHD BMT</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients age 0 65 year age . Patient must genotypically HLAidentical sibling , phenotypically match firstdegree relative unrelated match donor . Acute lymphocytic leukemia ( ALL ) CR1 high risk feature Acute myeloid leukemia ( AML ) CR1 high risk feature define : . Greater 1 cycle induction therapy require achieve remission , ii . Preceding myelodysplastic syndrome ( MDS ) myelofibrosis , secondary AML iii . Presence Flt3 mutation internal tandem duplication , iv . FAB M6 M7 classification adverse cytogenetics overall survival associate MDS , M6 , M7 leukemia , v. Complex karyotype [ &gt; 3 abnormality ] Acute Leukemias 2nd great remission Refractory Relapsed AML AML transform MDS Myelodysplastic syndrome ( MDS ) beyond refractory anemia Chronic myeloid leukemia ( CML ) Chronic myelomonocytic leukemia Philadelphianegative myeloproliferative disorder Relapsed chemotherapysensitive Hodgkin 's NonHodgkin 's lymphoma Multiple MyelomaStage III Prior autologous allogeneic stem cell transplant . Performance status great 2 Active infection . Inadequate cardiac function ; arrythmias symptomatic cardiac disease . Inadequate pulmonary function ; FEV1 , FVC , DLCO &lt; 50 % predicted Inadequate Serum creatinine clearance &lt; 60 InadequatebHepatic function Positive serology HIV1 , 2 HTLV1 , 2 . Pregnancy . Female patient must negative pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Acute lymphocytic leukemia ( ALL )</keyword>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>Acute Leukemia</keyword>
	<keyword>Refractory Relapsed AML</keyword>
	<keyword>Myelodysplastic syndrome ( MDS )</keyword>
	<keyword>Chronic myeloid leukemia ( CML )</keyword>
	<keyword>Chronic myelomonocytic leukemia</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Philadelphia-negative myeloproliferative disorder</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Bone Marrow</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Related donor</keyword>
	<keyword>unrelated donor</keyword>
</DOC>